Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis

Journal of Neurology

Volumn 262, Issue 5, 2015, Pages 1115-1119

  Iorio, Raffaele ^a   Damato, Valentina ^b   Alboini, Paolo Emilio ^b   Evoli, Amelia ^b  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antibodies; Immunotherapy; Myasthenia gravis; Rituximab

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN G; MUSCLE PROTEIN; MUSCLE SPECIFIC KINASE; RITUXIMAB; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

BRONCHITIS; CLINICAL FEATURE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GIARDIASIS; HEART FAILURE; HERPES ZOSTER; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS; MYASTHENIA GRAVIS; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; MEDLINE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

HUMANS; IMMUNOLOGIC FACTORS; MYASTHENIA GRAVIS; PUBMED; RITUXIMAB; TREATMENT OUTCOME;

EID: 84929840939     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7532-3     Document Type: Review

References (44)

1. Meriggioli MN, Sanders DB (2012) Muscle antibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol 8:427–438
2. Verschuuren JJ, Huijbers MG, Plomp JJ et al (2013) Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 12:918–923
3. Skeie GO, Apostolski S, Evoli A et al (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893–902
4. Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA (2008) Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci 1132:305–314
5. Reff ME, Carner K, Chambers KS et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445
6. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR (2009) A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9:10–25
7. Iorio R, Pittock SJ (2014) Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies. Clin Exp Neuroimmunol 5:175–187
8. Iorio R, Assenza G, Tombini M, Colicchio G, Della Marca G, Benvenga A, Damato V, Rossini PM, Vollono C, Plantone D, Marti A, Batocchi AP, Evoli A (2014) The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy. Eur J Neurol. doi:10.1111/ene.12529
9. Zaja F, Russo D, Fuga G, Perella G, Baccarani M (2000) Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55:1062–1063
10. Wylam M, Anderson P, Kuntz NL, Rodriguez V (2003) Successful treatment of refractory myasthenia gravis using Rituxomab: a pediatric case report. J Pediatr 143:674–677
11. Gajra A, Vajpayee N, Grethlein SJ (2004) Response of myasthenia gravis to rituximab in a patient with non-hodgkin lymphoma. Am J Hematol 77:196–197
12. Takagi K, Yoshida A, Iwasaki H, Inoue H, Ueda A (2005) Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma. Ann Hematol 84:548–550
13. Lin PT, Martin BA, Weinacker AB, So YT (2006) High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve 33:433–435
14. Hain B, Jordan K, Deschauer M, Zierz S (2006) Successful treatment of Musk-antibody positive myasthenia gravis with Rituximab. Muscle Nerve 33:575–580
15. Thakre M, Inshasi J, Marashi M (2007) Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 254:968–969
16. Chan A, Lee DH, Linker R, Mohr A, Toyka KV, Gold R (2007) Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 254(11):1604–1606
17. Baek WS, Bashey A, Sheean GL (2007) Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatry 78:771
18. Kerkeni S, Marotte H, Miossec P (2008) Improvement with Rituximab in a patient with both rheumatoid arthritis and myasthenia gravis. Muscle Nerve 38:1343–1345
19. StroberJ MD, Cowan MJ, Horn BN (2009) Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol 66:659–661
20. Stieglbauer K, Topakian R, Schäffer V, Aichner FT (2009) Rituximab for myasthenia gravis. Three case reports and review of the literature. J Neurol Sci 280:120–122
21. Tzaribachev N, Schedel J, Koetter I, Kuemmerle-Deschner JB (2009) Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2:6609
22. Masroujeh R, Otrock ZK, Yamout B, Jabbour MN, Bazarbachi A (2010) Myasthenia gravis developing in a patient with CNS lymphoma. Int J Hematol 91:522–524
23. Sadnicka A, Reill MM, Mummery C, Brandner S, Hirsch N, Lunn MP (2011) Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis. J Neurol Neurosurg Psychiatry 82:230–232
24. Lau AYL, Chan AYY, Mok VCT (2011) Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody–positive myasthenia gravis: response to cyclophosphamide and rituximab treatment. Hong Kong Med J 17:77–79
25. Kuntzer T, Carota A, Novy J, Cavassini M, Du Pasquier RA (2011) Rituximab is successful in an HIV-positive patient with Musk myasthenia gravis. Neurology 76:757–758
26. Koul R, Al Futaisi A, Abdwani R (2012) Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature. Pediatr Neurol 47:209–212
27. Jakubikova M, Pitha J, Latta J, Ehler E, Schutzner J (2013) Myasthenia gravis, Castleman disease, pemphigus and anti-phospholipid syndrome. Muscle Nerve 47:447–451
28. Renard D, Cornillet L, Castelnovo G (2013) Myocardial infarction after rituximab infusion. Neuromuscul Disord 23:599–601
29. Yi JS, Decroos EC, Sanders DB, Weinhold KJ, Guptill JT (2013) Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. Muscle Nerve 48:992–993
30. Sun F, Ladha SS, Yang L, Liu Q, Shi SX, Su N, Bomprezzi R, Shi FD (2014) Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. Muscle Nerve 49:487–494
31. Jaretzki A, Barohn RB, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Neurology 55:16–23
32. Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, Amadori S (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112:1147–1150
33. Leandro MJ, Becerra-Fernandez E (2011) B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 25:535–548
34. Cobo-Ibáñez T, Loza-Santamaría E, Pego-Reigosa JM, Marqués AO, Rúa-Figueroa I, Fernández-Nebro A, Cáliz RC, López Longo FJ, Muñoz-Fernández S (2014) Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum (Epub ahead of print)
35. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54(2):613–620
36. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN (2007) Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 123:66–73
37. Catzola V, Battaglia A, Buzzonetti A, Fossati M, Scuderi F, Fattorossi A, Evoli A (2013) Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. J Neurol 260:2163–2165
38. Benucci M, Manfredi M, Puttini PS, Atzeni F (2010) Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today? Autoimmun Rev 9:801–803
39. Hultin LE, Hausner MA, Hultin PM, Giorgi JV (1993) CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 14:196–204
40. Huang H, Benoist C, Mathis D (2010) Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA 107:4658–4663
41. Winter O, Dame C, Jundt F, Hiepe F (2012) Pathogenic long-lived plasma cells their survival niches in autoimmunity, malignancy, and allergy. J Immunol 189:5105–5111
42. Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas-García R, Suárez-Calvet X, Muñoz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, Juárez C, Verschuuren JJ, Illa I (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78:189–193
43. HERMES Trial Group, Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676–688
44. Mahévas M, Michel M, Weill JC, Reynaud CA (2013) Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy. Front Immunol 4:494